Pulmonary vasodilator use in very preterm infants in United States children’s hospitals
2024

Use of Pulmonary Vasodilators in Very Preterm Infants

Sample size: 37428 publication 10 minutes Evidence: moderate

Author Information

Author(s): Bamat Nicolas, Vega Tomas, Huber Matthew, Jensen Erik, Avitabile Catherine, Lorch Scott, Gibbs Kathleen, O’Byrne Michael, Frank David

Primary Institution: The Children’s Hospital of Philadelphia

Hypothesis

To describe common pulmonary vasodilators, exposure timing, and characteristics associated with their use in very preterm infants.

Conclusion

Early inhaled nitric oxide and late sildenafil are used in very preterm infants despite limited evidence.

Supporting Evidence

  • 6.3% of infants received pulmonary vasodilators during the study period.
  • Early exposure to inhaled nitric oxide was associated with lower gestational age.
  • Late exposure to sildenafil was associated with higher grades of bronchopulmonary dysplasia.

Takeaway

Doctors often give special medicines to help the lungs of very tiny babies, but we need to study them more to make sure they really help.

Methodology

Observational study of very preterm infants discharged from U.S. children’s hospitals from 2011 to 2021, identifying pulmonary vasodilator exposures and using multivariable modeling.

Potential Biases

Potential misclassification bias due to reliance on ICD codes for diagnosis and treatment.

Limitations

The study could not determine precise indications for pulmonary vasodilator use and relied on administrative data, which may be subject to misclassification bias.

Participant Demographics

Infants born between 22 and 31 weeks gestational age, with a median length of stay of 67 days.

Statistical Information

P-Value

p<0.001

Confidence Interval

9.2 (7.3–11.7)

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.21203/rs.3.rs-5492163

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication